Status:
COMPLETED
A Biorepository for Coronary Heart Disease in Qatar
Lead Sponsor:
Hamad Medical Corporation
Collaborating Sponsors:
Mayo Clinic
Conditions:
Coronary Heart Disease (CHD)
Eligibility:
All Genders
18+ years
Brief Summary
Coronary heart disease (CHD) poses a major health burden in the Gulf countries. It is the leading cause of mortality and morbidity in the world and poses an enormous societal burden in the Gulf countr...
Detailed Description
INTRODUCTION: Prediction of Coronary heart disease (CHD) events is based on conventional risk factors for atherosclerosis such as age, sex, blood pressure, diabetes, lipid levels, and smoking status....
Eligibility Criteria
Inclusion
- Subjects: History or clinical diagnosis of Acute Coronary Syndrome
- Controls: No history of Coronary Heart disease.
Exclusion
- Chronic or infectious disease
- Vulnerable populations (Children, prisoners, cognitive impairment)
Key Trial Info
Start Date :
January 31 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 18 2018
Estimated Enrollment :
2100 Patients enrolled
Trial Details
Trial ID
NCT03427489
Start Date
January 31 2013
End Date
March 18 2018
Last Update
August 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar, 3050